Correlation Between Karyopharm Therapeutics and Sellas Life

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Sellas Life at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Sellas Life into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Sellas Life Sciences, you can compare the effects of market volatilities on Karyopharm Therapeutics and Sellas Life and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Sellas Life. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Sellas Life.

Diversification Opportunities for Karyopharm Therapeutics and Sellas Life

0.8

Correlation Coefficient

Karyopharm Therapeutics  Sellas Life

Very poor diversification

The 3 months correlation between Karyopharm and Sellas is 0.8. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Sellas Life Sciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sellas Life Sciences and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Sellas Life. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sellas Life Sciences has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Sellas Life go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Sellas Life

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Sellas Life. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 1.01 times less risky than Sellas Life. The stock trades about -0.03 of its potential returns per unit of risk. The Sellas Life Sciences is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  345.00  in Sellas Life Sciences on October 13, 2024 and sell it today you would lose (250.00) from holding Sellas Life Sciences or give up 72.46% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Sellas Life Sciences

Karyopharm Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Karyopharm Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the recent confusion on Wall Street may also be a sign of long-lasting gains for the firm traders.

Sellas Life Sciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Sellas Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with Karyopharm Therapeutics and Sellas Life

The main advantage of trading using opposite Karyopharm Therapeutics and Sellas Life positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Sellas Life can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sellas Life will offset losses from the drop in Sellas Life's long position.

The idea behind Karyopharm Therapeutics and Sellas Life Sciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.